Maas Biolab Overview
- Founded
-
1997
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
Maas Biolab General Information
Description
Operator of a biotechnology firm intended to develop a neuro-pharmaceutical drug. The company's services develop a treatment for chronic neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer's, Parkinson's and Huntington's, enabling healthcare practitioners to access advanced drugs for better treatment.
Contact Information
Website
www.maasbiolab.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- 23 Abanico Road
- Santa Fe, NM 87508
- United States
+1 (505) 000-0000
Maas Biolab Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 01-Mar-2021 | 0000 | Completed | Generating Revenue | ||
| 2. Grant | 01-Jan-2007 | 00.000 | 0000 | Completed | Generating Revenue | |
| 1. Later Stage VC | 25-Apr-2006 | $50K | $50K | Completed | Generating Revenue |
Maas Biolab Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Maas Biolab Patents
Maas Biolab Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2003229835-A1 | Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier | Inactive | 22-Feb-2002 | 000000000 | |
| AU-2003229835-A8 | Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier | Inactive | 22-Feb-2002 | 000000000 | |
| FR-2836474-B1 | Compounds, compositions and method for transporting cyclosporin molecules through the hematoencephalic barrier | Inactive | 22-Feb-2002 | 000000000 | |
| FR-2836474-A1 | New cyclosporin derivatives, containing bonded peptide vector for crossing blood-brain barrier, used for treating cerebral disorders such as neurodegenerative diseases, cerebral trauma or cerebrovascular accidents | Active | 22-Feb-2002 | 000000000 | 0 |
| US-20040147433-A1 | Preparing a dosage of a neuroimmunophilin ligand selected from cyclosporins and functional derivatives, metabolites, variants, and salts thereof which are able to cross the blood-brain barrier; administering that dosage | Inactive | 14-Jun-2001 | A61K38/13 |
Maas Biolab Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Marcus Keep MD | Chief Executive Officer | ||
| Michael Vickers | Director of Operations | ||
| Eskil Elmér | Founder | ||
| Cesar Borlongan Ph.D | Head of Scientific Advisory Board |
Maas Biolab Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
